SELLAS Life Sciences (SLS) EBIT (2011 - 2026)
SELLAS Life Sciences' (SLS) quarterly EBIT came in at -$9.3 million in Q1 2026, down 52.6% year-on-year from -$19.5 million in Q1 2025, and down 12.08% on a QoQ basis from -$8.3 million in Q4 2025.
SELLAS Life Sciences (SLS) EBIT (2011 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 14 years of EBIT data on file, last reported at -$9.3 million in Q1 2026.
- On a quarterly basis, EBIT fell 52.6% year-over-year to -$9.3 million in Q1 2026; TTM through Mar 2026 was -$31.5 million, a 12.65% decrease from a year earlier, with the FY2025 full-year figure at -$28.3 million, up 10.28% from the prior year.
- EBIT for Q1 2026 stood at -$9.3 million, down from -$8.3 million in the prior quarter.
- Over the last five years, EBIT for SLS reached as high as -$6.1 million in Q1 2025 and fell as low as -$16.7 million in Q1 2022.
- Historically, EBIT has averaged -$8.8 million across 5 years, with a median of -$8.3 million in 2025.
- Across the five-year window, EBIT sank 645.43% in 2022 and soared 37.14% in 2025, its largest moves.
- Year by year, EBIT stood at -$9.4 million in 2022, then advanced by 13.43% to -$8.2 million in 2023, then grew by 15.4% to -$6.9 million in 2024, then declined by 19.33% to -$8.3 million in 2025, then retreated by 12.08% to -$9.3 million in 2026.
- Per Business Quant data, the three most recent EBIT figures were -$9.3 million in Q1 2026, -$8.3 million in Q4 2025, and -$7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | -9.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.25 Mn |
| Dec 31, 2025 | -8.26 Mn |
| Sep 30, 2025 | -7.08 Mn |
| Jun 30, 2025 | -6.87 Mn |
| Mar 31, 2025 | -6.06 Mn |
| Dec 31, 2024 | -6.92 Mn |
| Sep 30, 2024 | -7.33 Mn |
| Jun 30, 2024 | -7.62 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Sep 30, 2023 | -9.36 Mn |
| Jun 30, 2023 | -9.05 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | -6.98 Mn |
| Jun 30, 2021 | -4.45 Mn |